Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
Read More…
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone650-243-6300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$92.01 million
Profitability
Miscellaneous
Employees270
Next Earnings Date7/22/2019 (Estimated)
OptionableOptionable
Veracyte (NASDAQ:VCYT) Frequently Asked Questions
What is Veracyte's stock symbol?
Veracyte trades on the NASDAQ under the ticker symbol "VCYT."
How were Veracyte's earnings last quarter?
Veracyte Inc (NASDAQ:VCYT) announced its quarterly earnings data on Tuesday, April, 30th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.05. The biotechnology company earned $29.53 million during the quarter, compared to the consensus estimate of $28.20 million. Veracyte had a negative return on equity of 23.43% and a negative net margin of 15.51%. View Veracyte's Earnings History.
When is Veracyte's next earnings date?
What price target have analysts set for VCYT?
4 equities research analysts have issued 1 year target prices for Veracyte's shares. Their predictions range from $11.00 to $17.00. On average, they anticipate Veracyte's stock price to reach $13.4333 in the next twelve months. This suggests that the stock has a possible downside of 51.3%. View Analyst Price Targets for Veracyte.
What is the consensus analysts' recommendation for Veracyte?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veracyte.
Has Veracyte been receiving favorable news coverage?
Press coverage about VCYT stock has been trending somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Veracyte earned a news impact score of 1.2 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Veracyte.
Who are some of Veracyte's key competitors?
Some companies that are related to Veracyte include Genomic Health (GHDX), InVitae (NVTA), Natera (NTRA), CareDx (CDNA), RadNet (RDNT), Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), Miragen Therapeutics (MGEN), Psychemedics (PMD), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), Cancer Genetics (CGIX) and CBA Florida (CBAI).
What other stocks do shareholders of Veracyte own?
Who are Veracyte's key executives?
Veracyte's management team includes the folowing people:
- Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)
- Mr. Christopher M. Hall, Pres & COO (Age 50)
- Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)
- Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)
- Mr. Ashish Kheterpal, Chief Information Officer
Who are Veracyte's major shareholders?
Veracyte's stock is owned by many different of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (8.31%), Gilder Gagnon Howe & Co. LLC (8.29%), Nikko Asset Management Americas Inc. (1.46%), Sumitomo Mitsui Trust Holdings Inc. (1.43%), William Blair Investment Management LLC (1.14%) and Laurion Capital Management LP (0.85%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy and Jesse I Treu. View Institutional Ownership Trends for Veracyte.
Which major investors are selling Veracyte stock?
VCYT stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Pier Capital LLC, Marshall Wace LLP, Quantum Capital Management, Algert Global LLC, Fiera Capital Corp, ARK Investment Management LLC and Strs Ohio. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Giulia C Kennedy and Jesse I Treu. View Insider Buying and Selling for Veracyte.
Which major investors are buying Veracyte stock?
VCYT stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., William Blair Investment Management LLC, Laurion Capital Management LP, Robeco Institutional Asset Management B.V., Spark Investment Management LLC and Cadence Capital Management LLC. View Insider Buying and Selling for Veracyte.
How do I buy shares of Veracyte?
Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Veracyte's stock price today?
One share of VCYT stock can currently be purchased for approximately $27.57.
How big of a company is Veracyte?
Veracyte has a market capitalization of $1.15 billion and generates $92.01 million in revenue each year. The biotechnology company earns $-23,000,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Veracyte employs 270 workers across the globe.View Additional Information About Veracyte.
What is Veracyte's official website?
How can I contact Veracyte?
Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]
MarketBeat Community Rating for Veracyte (NASDAQ VCYT)
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe VCYT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
